Platelet-released proteins as molecular markers for the activation process
- PMID: 6240116
- DOI: 10.1055/s-2007-1004432
Platelet-released proteins as molecular markers for the activation process
Abstract
The desire to have a specific, sensitive marker for platelet activation was originally thought to lie in the development of RIAs for BTG and PF4. Although this wish has not been denied, the interpretation of the information obtained from such an analysis has proved far less rewarding. The principal challenge of these procedures is based upon the lack of a cause and effect relationship between a given disease and platelet activation, coupled with the differential clearance rate and mechanism for each of the discussed proteins. Thus, we have seen that the renal clearance rate and mechanism for each of the discussed proteins. Thus, we have seen that the renal clearance of a patient should be noted prior to interpreting the elevation of BTG. Similarly, since PF4 is removed from the circulation so rapidly, its plasma values tend to be lower than BTG by a factor of 5, although the significance of the BTG to PF4 ratio is questioned. Administration of heparin results in a heparin-induced increase in plasma PF4 levels but not for BTG, and this PF4 increase can be as great as 20-fold. PF4 and BTG values are also directly increased by pressure increases. Taken individually, these mediators each compromise the ability to correlate the significance of platelet protein increases with any single pathologic condition. When viewed collectively, an analysis of platelet-released proteins is best interpreted as an indication that the functional integrity of the platelet has been perturbed; the direct relationship of disease processes to platelet release is far from certain and is simply documented by the use of such described procedures. The final note of caution for these assays is to be found in the recent summary analysis of the standardization of both BTG and PF4. In this study, considerably greater variation among laboratories was noted for PF4 than was seen for BTG, and the study directors concluded that comparisons of results between laboratories should be regarded as unreliable due mainly to the use of different standards for each protein in a given laboratory. The final note of caution for these assays is to be found in the recent summary analysis of the standardization of both BTG and PF4. In this study, considerably greater variation among laboratories was noted for PF4 than was seen for BTG, and the study directors concluded that comparisons of results between laboratories should be regarded as unreliable due mainly to the use of different standards for each protein in a given laboratory.
Similar articles
-
Detection of enhanced in vivo platelet alpha-granule release in different patient groups--comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays.Thromb Haemost. 1984 Oct 31;52(2):183-7. Thromb Haemost. 1984. PMID: 6084323
-
Platelet factor 4 (PF4) and heparin released platelet factor 4 (HR-PF4) in diabetes mellitus. Effect of the duration of the disease.Folia Haematol Int Mag Klin Morphol Blutforsch. 1986;113(5):646-54. Folia Haematol Int Mag Klin Morphol Blutforsch. 1986. PMID: 2435630
-
Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia.Platelets. 2003 Nov-Dec;14(7-8):407-11. doi: 10.1080/09537100310001638814. Platelets. 2003. PMID: 14713509
-
A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex.Semin Thromb Hemost. 2004 Jun;30(3):359-68. doi: 10.1055/s-2004-831049. Semin Thromb Hemost. 2004. PMID: 15282659 Review.
-
Are platelet factor 4 and beta-thromboglobulin markers of cardiovascular disorders?Ric Clin Lab. 1984 Jan-Mar;14(1):9-18. doi: 10.1007/BF02905035. Ric Clin Lab. 1984. PMID: 6203164 Review.
Cited by
-
Guidelines for the Management of Patients with Acute Myocardial Infarction.J Thromb Thrombolysis. 1998;5(1):73-81. doi: 10.1023/A:1008809723703. J Thromb Thrombolysis. 1998. PMID: 10608054 No abstract available.
-
Markers for endothelial injury, clotting and platelet activation in preeclampsia.Arch Gynecol Obstet. 1992;251(3):105-10. doi: 10.1007/BF02718370. Arch Gynecol Obstet. 1992. PMID: 1605673
-
Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease.Front Cardiovasc Med. 2021 Jun 21;8:684920. doi: 10.3389/fcvm.2021.684920. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34235190 Free PMC article. Review.
-
Persistent activation of thrombocytes in neurosurgical patients operated for primary brain tumours.Acta Neurochir (Wien). 1993;121(3-4):146-8. doi: 10.1007/BF01809266. Acta Neurochir (Wien). 1993. PMID: 8512011
-
Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition.J Thromb Thrombolysis. 1998;5(1):65-71. doi: 10.1023/A:1008861707773. J Thromb Thrombolysis. 1998. PMID: 10608053
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous